GSK Opts In On Ionis’ Antisense Candidates For Hep B

 
• By Joseph Haas

The pharma is taking over a pair of Ionis candidates intended to address the underlying cause of HBV, possibly offering a curative therapy. It’s just the second HBV licensing agreement in 2019, after heavier deal flow in recent years.

Wooden block form the word HEP B with stethoscope. Medical concept.
The next frontier in hepatitis B therapy is curing the virus

More from Deals

More from Business